(1) The main objective of the choice of angina medication is to improve the prognosis. Aspirin and lipid-lowering therapy can effectively reduce the risk of mortality and nonfatal myocardial infarction for primary and secondary prevention purposes, and are effective therapeutic agents for the prevention of cardiac accidents in patients with stable angina. (2) Beta-blockers are the drugs of choice for stable angina pectoris. (3) Treatment with nitrate preparations has not been shown to be effective in reducing mortality in patients with coronary artery disease. (4) Rapid-release or short-acting dihydropyridine calcium antagonists (e.g., cardioplegia) have been associated with increased adverse cardiac events, whereas long-acting or extended-release dihydropyridine calcium antagonists (e.g., nifedipine extended-release tablets and bexamethasone) or non-dihydropyridine calcium antagonists (e.g., hapten) can relieve symptoms in patients with stable angina without increasing the incidence of adverse cardiac events. (5) Long-acting calcium antagonists are superior to long-acting nitrate preparations for long-term treatment of angina pectoris symptom relief. (6) A new generation of long-acting dihydropyridine calcium antagonists with vasoselective properties (e.g., Loxodren) can be used in patients with poor left ventricular systolic function. (7) Patients with sinus node dysfunction, bradycardia at rest or atrioventricular block should not use β-blockers or calcium antagonists that slow down the heart rate. (8) In cardiac patients with insulin-dependent diabetes mellitus (i.e., type 1 diabetes), β-blockers may mask hypoglycemic symptoms.